EGFR ex20ins患者从传统化疗、第一代、第二代、第三代EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)和免疫治疗中的获益有限。近期,如埃万妥单抗(Amivantamab,JNJ-6372)、莫博赛替尼(Mobocertinib,TAK-788)、舒沃替尼(Sunv...
27. Yang, Z. etal. Investigating novel resistance mechanisms to third-generation EGFR tyrosinekinase inhibitor osimertinib in non-small cell lung cancer patients. Clin.Cancer Res. 24, 3097–3107 (2018). 28. Ou, S. I....
从上世纪九十年代开始,针对EGFR这一个抗肿瘤靶点,不同研究者开展了不同的药物开发策略。从已上市产品来看,主要有抑制细胞外配体-受体结合的EGFR单抗类药物,和抑制细胞内ATP-TK结合的TKI(tyrosine kinase inhibitor)小分子化学药物。 由于单抗类药物和TKI类药物的开发策略、适用人群、检测方法、伴随诊断解决方案不同,下...
小分子酪氨酸激酶抑制剂(Tyrosine kinase inhibitor,TKI)如EGFR-TKI、ALK-TKI等是一类重要的NSCLC治疗药物,疗效显著且有多款为临床一线用药,但目前均面临临床耐药的挑战,亟需开发更多药物来改善耐药患者预后,助力NSCLC治疗。 作者| betaloc 01三代TKI是临床主力,但均已出现耐药 EGFR突变是中国NSCLC患者的第一大驱动基因...
英文名:Gefitinib, EGFR tyrosine kinase inhibitor;ZD1839; CAS号:184475-35-2 结构式:COc1cc2c(cc1OCCCN3CCOCC 发布于 2023-03-10 14:27・IP 属地天津 还没有评论,发表第一个评论吧 登录知乎,您可以享受以下权益: 更懂你的优质内容 更专业的大咖答主 ...
5. Oxnard G R , Arcila M E , Sima C S , et al. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation[J]. Clinical Cancer Research, 2011, 17(6):1616-1622. ...
Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction. Tumour Biol. 2015;36:2993e2999.Lixia, ZhangXiaokun, YangBei, ZhaoZhen, Cai. (2015) Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous ...
OBJECTIVEIn obesity, an increased macrophage infiltration in adipose tissue occurs, contributing to low-grade inflammation and insulin resistance. Epidermal growth factor receptor (EGFR) mediates both chemotaxis and proliferation in monocytes and macrophages. However, the role of EGFR inhibitors in this su...
7.Yu Helena A, Goto Yasushi, Hayashi Hidetoshi et al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemoth...
如涉嫌侵犯您的著作权请联系我们删除，谢谢!参考资料 1.EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib | NEJM 2.BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer - PMC (nih.gov)